Positions

Overview

  • Dr. deShazo sees patients with a variety of solid tumors and is especially interested in lung and genitourinary malignancies. She has taught medical students Introduction to Clinical Medicine for more than 5 years and was recently selected as one of ten faculty designated as Core Clinical Faculty for the Department of Internal Medicine Residency training program.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR) 2021
    2019 Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical CenterJournal of the American College of Radiology.  16:315-320. 2019
    2017 Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancerLung Cancer.  106:125-130. 2017
    2015 The Physician Abuse of Meaningful UseJournal of the Mississippi State Medical Association.  56:344-345. 2015
    2015 Effect of African-American Race on Tumor Recurrence after Radical Cystectomy for Urothelial Carcinoma of the BladderClinical Genitourinary Cancer.  13:469-475. 2015
    2014 Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapyUrologic Oncology: Seminars and Original Investigations.  32:501-508. 2014
    2013 Erratum to "Management of squamous cell carcinoma of the head and neck in the elderly: Review and recommendations" [J. Geriatr. Oncol. 3 (2012) 265-272]Journal of Geriatric Oncology.  4:98. 2013
    2012 Management of squamous cell carcinoma of the head and neck in the elderly: Review and recommendationsJournal of Geriatric Oncology.  3:265-272. 2012
    2012 Senior adult oncology: Clinical practice guidelines in oncology 2012
    2012 Treatment of non-small cell lung cancer in the older patient 2012
    2009 Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacyCancer Chemotherapy and Pharmacology.  63:731-743. 2009

    Principal Investigator On

  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2017 - 2021
  • Private Grant  awarded by AMGEN, INC.^ 2018 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017 - 2020
  • Investigator On

  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2021 - 2026
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • Private Grant  awarded by ARCUS BIOSCIENCES INC 2020 - 2025
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2025
  • UAB 1984: Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and/or Nivolumab  awarded by CLEVELAND CLINIC FOUNDATION 2020 - 2024
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2019 - 2024
  • Private Grant  awarded by QED THERAPEUTICS INC 2020 - 2024
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2024
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2024
  • Private Grant  awarded by IMMUNOMEDICS, INC. 2021 - 2024
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2020 - 2023
  • Private Grant  awarded by PROSTATE CANCER CLINICAL TRIALS CONSORTIUM, LLC 2017 - 2022
  • UAB 1661: Randomized Phase II Trial Comparing Sequential First-Line Sunitinib and Second-Line Avelumab Versus First-Line Avelumab and Second-Line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial  awarded by HOOSIER CANCER RESEARCH NETWORK 2017 - 2022
  • Private Grant  awarded by MEDIVATION, INC 2019 - 2022
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2021
  • UAB 1395 - Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer  awarded by KARMANOS CANCER CENTER 2019 - 2021
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^ 2016 - 2021
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2017 - 2021
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2021
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2021
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2020
  • Private Grant  awarded by ACERTA PHARMA B.V. 2017 - 2020
  • Private Grant  awarded by JOUNCE THERAPEUTICS, INC 2020
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^ 2017 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2017 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by ASTRAZENECA AB 2018 - 2020
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2019 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by Bayer HealthCare 2017 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Private Grant  awarded by MEDIVATION, INC 2015 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by MERCK & COMPANY, INC. ^ 2017 - 2019
  • Private Grant  awarded by MedImmune 2015 - 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2013 - 2019
  • UAB 1395: Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs. Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer  awarded by KARMANOS CANCER CENTER 2014 - 2019
  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc. 2017 - 2019
  • UAB 1527 – A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer  awarded by Johns Hopkins University 2017 - 2019
  • Private Grant  awarded by EXELIXIS, INC. 2014 - 2019
  • Private Grant  awarded by STEM CENTRX 2014 - 2019
  • UAB 1360: Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-Muscle-Invasive Transitional Cell Bladder Cancer  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2014 - 2019
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2019
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION 2017 - 2018
  • Private Grant  awarded by STEM CENTRX 2016 - 2018
  • UAB 1311: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-Containing Regimen  awarded by HOOSIER ONCOLOGY GROUP 2013 - 2018
  • Private Grant  awarded by MEDIVATION, INC 2017 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2018
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC. 2016 - 2018
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by Bayer HealthCare 2015 - 2018
  • Private Grant  awarded by BELLICUM PHARMA 2013 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2018
  • Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma  awarded by HOOSIER ONCOLOGY GROUP 2013 - 2018
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2014 - 2018
  • Private Grant  awarded by AGENSYS 2014 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2015 - 2017
  • Private Grant  awarded by ACERTA PHARMA B.V. 2015 - 2017
  • A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)  awarded by Johns Hopkins University 2015 - 2017
  • Private Grant  awarded by HEAT BIOLOGICS 2015 - 2017
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^ 2015 - 2017
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2014 - 2017
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016 - 2017
  • Private Grant  awarded by CLOVIS ONCOLOGY 2015 - 2017
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016 - 2017
  • Private Grant  awarded by ASTRAZENECA AB 2014 - 2017
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2013 - 2017
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2016 - 2017
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION 2013 - 2017
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2013 - 2017
  • LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2016
  • Private Grant  awarded by ALPHA ONCOLOGY, INC 2013 - 2016
  • Private Grant  awarded by MEDIVATION, INC 2014 - 2016
  • Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors  awarded by HOOSIER ONCOLOGY GROUP 2013 - 2016
  • Private Grant  awarded by Sanofi US Services Inc 2011 - 2016
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC. 2014 - 2016
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015 - 2016
  • Private Grant  awarded by THRESHOLD PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by EMD SERONO 2015
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2015
  • Private Grant  awarded by Sanofi US Services Inc 2013 - 2015
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015
  • Private Grant  awarded by Genentech 2008 - 2015
  • Private Grant  awarded by MEDIVATION, INC 2012 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2015
  • Private Grant  awarded by ARAGON PHARMACEUTICALS 2013 - 2015
  • Private Grant  awarded by EISAI, INC. 2013 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2007 - 2014
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2011 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2013
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2012 - 2013
  • Education And Training

  • Doctor of Medicine in Internal Medicine Residency Program, University of Alabama at Birmingham 2000
  • UAB Hospital, Internship 2001
  • UAB Hospital, Residency 2003
  • UAB Hospital, Postdoctoral Fellowship 2006
  • Full Name

  • Mollie Deshazo